Results 211 to 220 of about 45,124 (301)

Size and Topography of the Brain's Functional Networks with Psychotic Experiences, Schizophrenia, and Bipolar Disorder. [PDF]

Biol Psychiatry Glob Open Sci
Mamah D, Chen SS, Gordon E, Kandala S, Barch DM, Harms MP.   +5 more
europepmc   +1 more source

Addressing limitations in current measurement practices of trauma assessment in minoritized populations

Journal of Traumatic Stress, EarlyView.
Abstract Standardized trauma assessment frameworks often fail to account for the unique experiences and symptom presentations of minoritized populations, including Black, Indigenous, and people of color (BIPOC) and sexual and gender minority (SGM) individuals, leading to methodological inequity.
Krithika Prakash, Selime R. Salim, Colin T. Mahoney, Phillip W. Schnarrs, Antonio A. Morgan‐López   +4 more
wiley   +1 more source

Imitative inhibitory control is associated with psychotic experiences in a sample from the general population. [PDF]

Front Psychiatry
Ulloa JL, Núñez DE, Gaspar PA, Brass M.   +3 more
europepmc   +1 more source

Chess in Mental Health: Therapeutic Potential and Neurocognitive Mechanisms—A Systematic Review

Medicine Bulletin, EarlyView.
ABSTRACT Objective Chess is an ancient game with simple rules but high cognitive demands. This review examined chess as a cognitive tool for patients with mental disorders and explored the cognitive mechanisms and neural structures that may underlie its effects. Method A systematic review of studies was conducted following PRISMA guidelines.
Maria Rodrigo‐Yanguas, Fernand Gobet, Marcos Bella‐Fernández, Marina Martin‐Moratinos, Hilario Blasco‐Fontecilla   +4 more
wiley   +1 more source

Epidemiological Signals, Knowledge Gaps, and Practice Considerations From the 2024 Functional Neurological Disorder Society International Meeting: A Conference Report With Narrative Synthesis

Medicine Bulletin, EarlyView.
ABSTRACT The 2024 International Conference on Functional Neurological Disorders brought together clinicians, researchers, advocates, and service‐user representatives to discuss recent developments in functional neurological disorder and related functional disorders.
Yadira Velazquez‐Rodriquez, Jennifer Brown, Katherine Gill   +2 more
wiley   +1 more source

Independent and joint effects of genomic and exposomic loads for schizophrenia on psychotic experiences in adolescents of European ancestry. [PDF]

Schizophrenia (Heidelb)
Di Vincenzo M, Prachason T, Sampogna G, Arias-Magnasco A, Lin BD, Pries LK, van Os J, Rutten BPF, Barzilay R, Fiorillo A, Guloksuz S.   +10 more
europepmc   +1 more source

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri, Bruno Bergmans, Eric Freire‐Alvarez, Lucie Hopes, Drew S. Kern, Robert S. Kirsner, Giulia Lazzeri, Pedro Mendes‐Bastos, Noriko Nishikawa, Per Odin, Karolina Poplawska‐Domaszewicz, Rajesh Pahwa, Yuval Ramot, Klaus Seppi, Tobias Warnecke, Robert Wiggins, Megha B. Shah, Pavnit Kukreja, Bjoern Fritz, Koray Onuk, Stuart H. Isaacson   +20 more
wiley   +1 more source

Parent-Rated Schizotypy and Clinician-Rated Psychotic Experiences in Early Adolescence as Predictors of Schizophrenia Diagnosis by Middle Adulthood. [PDF]

Schizophr Bull
O'Hare KJM, Poulton R, Linscott RJ.
europepmc   +1 more source

Continuous Subcutaneous Versus Intestinal Levodopa Infusion for Parkinson's Disease: A Real‐World, Monocentric, Observational Study and Critical Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Subcutaneous foslevodopa‐foscarbidopa (SCFF) is a novel, non‐surgical dopaminergic infusion therapy for better controlling motor fluctuations in advanced Parkinson's disease (PD). However, there are scarce real‐world data on efficacy, adverse events and comparisons with other infusion strategies. Objectives Here, we aimed to provide
Johannes Hartig, Lennert Sitzmann, Doreen Hartenstein, Marion Labisch, Chi Wang Ip, Jens Volkmann, Christine Daniels   +6 more
wiley   +1 more source